Global Liquid Biopsy Market

Liquid Biopsy Market Size, Share, Growth Analysis, By Product & Services (Assay Kits, Instruments), By Circulating Biomarker (CTCs, cfDNA), By Technology (NGS, PCR), By End User (hospitals and clinics, Diagnostics Centres), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35J2060 | Region: Global | Published Date: August, 2024
Pages: 219 | Tables: 61 | Figures: 75

Liquid Biopsy Market Insights

Global Liquid Biopsy Market was valued at around USD 9.28 Billion in 2022 and is expected to rise from USD 10.32 Billion in 2023 to reach a value of USD 24.14 Billion by 2031, at a CAGR of 11.21% during the forecast period (2024–2031). 

Global liquid biopsy market is growing rapidly due to its non-invasive nature and increasing incidence of cancer worldwide. Liquid biopsy offers a non-invasive alternative and offers, traditional histology allows for faster cancer diagnosis, monitoring and personalized therapy. Next generation sequencing (NGS) and polymer chain reaction (PCR) have dramatically increased the sensitivity and specificity of liquid biopsies, driving the market growth. Furthermore, the need for full validation and standardization of urine samples is an important limitation. Despite these challenges, the market is poised for significant growth, driven by ongoing R&D activities and increasing focus on personalized medicine. Some AI and ML algorithms are available that can analyze large data sets from liquid biopsy tests to identify the patterns and biomarkers associated with cancer, enabling identification and accurate and timely treatment. 

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Liquid Biopsy Market was valued at around USD 9.28 Billion in 2022 and is expected to rise from USD 10.32 Billion in 2023 to reach a value of USD 24.14 Billion by 2031, at a CAGR of 11.21% during the forecast period (2024–2031). 

The liquid biopsy market is quite fragmented, with the presence of numerous small and massive players. One notable example is the collaboration among the Guardant Health and AstraZeneca. The partnership to be introduced in 2020, objectives to combine Guardant Health's liquid analytics generation with AstraZeneca's oncology department to increase most cancers treatment and diagnosis. Invincible, actual-time inspection capable, as Essential for knowledgeable scientific choice making.  'F. Hoffmann-La Roche Ltd (Switzerland) ', 'Thermo Fisher Scientific Inc. (US) ', 'Illumina, Inc. (US) ', 'Guardant Health, Inc. (US) ', 'Biocept, Inc. (US) ', 'Sysmex Corporation (Japan) ', 'Menarini Silicon Biosystems (Italy) ', 'Natera, Inc. (US) ', 'Biocartis Group NV (Belgium) ', 'Personal Genome Diagnostics Inc. (US) ', 'Bio-Rad Laboratories, Inc. (US) ', 'OncoCyte Corporation (US) ', 'Adaptive Biotechnologies Corporation (US) ', 'Angle plc (United Kingdom) ', 'Epic Sciences, Inc. (US) ', 'NEOGENOMICS LABORATORIES (US) ', 'CellMax Life (US) ', 'MENARINI-SILICON BIOSYSTEMS (Italy) ', 'LUNGLIFE AI, INC. (US) ', 'VORTEX BIOSCIENCES (US)'

Next-generation sequencing (NGS) and polymer chain reaction (PCR) technologies have greatly improved the sensitivity and specificity of liquid screening tests, and increased adoption in clinical settings. 

North America dominated the market with a 50.76% revenue percentage in 2023, driven with the aid of heavy funding and the entry of numerous biotechnology corporations carrying out advanced trials. Despite the outbreak of most cancers, led by the rapid technological improvement and rising government policies. Various companies, including the American Society of Clinical Oncology (ASCO) are working to support the use of liquid biopsies, which are expected to boost revenue in this market over the forecast period. 

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Liquid Biopsy Market

Report ID: SQMIG35J2060

$5,300
BUY NOW GET FREE SAMPLE